All News from Accelerate Diagnostics

All News

Accelerate Diagnostics reports Q3 2017 financial results

Nov 02, 2017 — Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending September 30, 2017. The company further reported signed agreements for 295 instruments year to date; contracts for customer evaluations total 239 instruments while revenue generating placements grew to 56 across the U.S., European, and Middle East regions.

Continue reading ›

Third Quarter 2017 Conference Call Set for November 2nd

Oct 17, 2017 — Accelerate Diagnostics, Inc. will announce third quarter 2017 financial results at the close of U.S. financial markets on Thursday, November 2, 2017.

Continue reading ›

Accelerate Diagnostics Welcomes Dr. Romney Humphries as Chief Scientific Officer

Jul 31, 2017 — Accelerate Diagnostics, Inc. announced today the addition of Romney Humphries, PhD, D(ABMM), M(ASCP) to its executive management team as Chief Scientific Officer.

Continue reading ›

New data now available on the speed, accuracy and advantages of the Accelerate Pheno™ system

Jun 15, 2017 — Accelerate Diagnostics, Inc. showcased new data presented at ASM Microbe 2017 on the potential clinical and workflow benefits of faster susceptibility results using the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit.

Continue reading ›

Accelerate Diagnostics announces sizeable release of data at ASM Microbe 2017

May 30, 2017 — Accelerate Diagnostics, Inc. today announced that new data from 11 healthcare institutions covering more than 1,200 samples will be presented at the upcoming annual meeting of the American Society for Microbiology – ASM Microbe in New Orleans, LA.

Continue reading ›

Accelerate Diagnostics Announces Closing of $79.3 Million Upsized Offering

May 15, 2017 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced the closing of its previously announced underwritten public offering of 2,750,000 shares of its common stock today, upsized from the original share offering of 2,500,000 shares of common stock, at a previously disclosed public offering price of $28.85 per share. The gross proceeds to Accelerate Diagnostics from the offering are approximately $79.3 million before deducting underwriting commissions and discounts, and estimated offering expenses payable by the company.

Continue reading ›

Accelerate Diagnostics Reports 191 Instruments Under Contract and 3x Revenue Growth for First Quarter 2017

May 03, 2017 — Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending March 31, 2017 including signed customer evaluation contracts covering 169 instruments, 22 additional instruments converted into revenue generating placements, and revenue growth exceeding 325% of the same period in the prior year.

Continue reading ›

Accelerate Diagnostics Schedules Call to Review First Quarter 2017 Results for May 3rd

Apr 18, 2017 — Accelerate Diagnostics, Inc. announced today it will host a conference call on Wednesday, May 3rd, 2017 to discuss its first quarter 2017 financial results and commercial progress.

Continue reading ›

Fourth Quarter and Full Year 2016 Results

Feb 28, 2017 — Accelerate Diagnostics filed Fourth Quarter and Full Year 2016 financial results today. Access them directly on our website in the SEC filings section of our Investors page or through the Securities and Exchange Commission’s (SEC) website.

Continue reading ›

Accelerate Diagnostics Receives FDA Marketing Authorization for the Accelerate Pheno™ System and Accelerate PhenoTest™ BC Kit

Feb 24, 2017 — Accelerate Diagnostics, Inc. (Accelerate) today announced that the U.S. Food and Drug Administration has granted the de novo request to market the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for identification and antibiotic susceptibility testing of pathogens directly from positive blood culture samples. The blood culture kit is indicated for susceptibility testing of specific pathogenic bacteria commonly associated with bacteremia, the leading cause of sepsis.

Continue reading ›